Real World Observation of SGLT2 Inhibitors on Clinical Outcomes and Heart Muscle Changes in Type 2 Diabetes Patients after Acute Myocardial Infarction A Prospective, Multi-center Registry Study

What this Trial Is About

Researchers are studying type 2 diabetes patients who have had an acute myocardial infarction (heart attack) and were treated with percutaneous coronary intervention (PCI). The study aims to find the best oral medicine to manage diabetes in these patients and to see if SGLT2 inhibitors can reduce cardiovascular events and improve heart remodeling after the heart attack. This research addresses a gap because, while SGLT2 inhibitors have shown cardiovascular benefits in diabetes patients without heart disease, their effects after acute myocardial infarction have not been studied. Participants who have had PCI for acute myocardial infarction and type 2 diabetes will be started on SGLT2 inhibitors within one month before or after PCI. The study is conducted across eight hospitals in South Korea affiliated with the Catholic University of Korea. A control group of 3,000 patients will be selected from a previous study cohort using similar criteria but without SGLT2 inhibitor treatment. This setup allows comparison between those treated with SGLT2 inhibitors and those who were not. During the study, researchers will monitor major adverse cardiac and cerebrovascular events over two years. The study includes careful evaluation of heart function and remodeling after myocardial infarction. Patient data from multiple hospitals will be collected and analyzed to understand how SGLT2 inhibitors may affect clinical outcomes and heart changes in this specific group of patients. Safety and long-term effects will be observed throughout the follow-up period.

SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study